Phospholipase A2 inflammatory marker release during elective coronary stenting

The release of phospholipase A2 inflammatory markers during percutaneous coronary intervention in patients with significant coronary stenosis and their relationship with angiographic, biochemical and epidemiologic factors.

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12611000875909

Acronym

PLAPCI biomarker study

Enrollment

250

Registered

2011-08-17

Start date

2011-10-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The aim of this study is to measure the release of PLA2 enzymes during elective coronary stenting in patients with coronary artery disease and to compare this release with known characteristics of the patient and their current treatment.

Interventions

The amount of PLA2 enzymes prior to and after elective coronary stenting (measured from a blood sample approximately 30 minutes apart)

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

Patients undergoing elective percutaneous coronary intervention aged 18 to 85 years. For the comparator group patients included will be aged 18 to 85 and undergoing elective coronary angiography only.

Exclusion criteria

Myocardial ischaemic event <14 days prior to participation Change in HMG-CoA reductase inhibitor(statin) in last 30 days Current acute or chronic inflammatory condition

Outcome results